

FIG. 1A




FIG. 1B





FIG. 1C






FIG. 1E




FIG. 2A




FIG. 2B





FIG. 2C



7/21

FIG. 2D





FIG. 2E



8/21

FIG. 3A






FIG. 3B



9/21

FIG. 3C



10/21

FIG. 3D





FIG. 3E



11/21

FIG. 3F




FIG. 4A





FIG. 4B

Tumor Type	{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}	
	NCC-HN19	NCC-HN137	NCC-HN64	NCC-HN148	NCC-HN124	NCC-HN43	NCC-HN1	NCC-HN154	NCC-HN159	NCC-HN180				
Genotype	AA	AA	AA	AA	AG	GG	GG	GG	GG	GG	GG	GG	GG	GG
Cell line Gefitinib IC50 (uM)	0.07	0.2	0.257	0.583	11.355	9.5	11	-	-	-	-	-	-	> 20
Relative AS1 Fold Change	0.37	1.22	0.17	1.00	16.43	1.34	1.04	1.88	7.43	1.14	1.14	1.14	1.14	1.14
Relative Isoform D/A Fold Change	0.05	15.453	0.01	1.982	1.000	0.83	1.00	0.132	0.002	0.096	0.096	0.096	0.096	0.096
RNA scope (AMP1 score) on FFPE tissue														
EGFR AS1	-	0	0	0	0	1+	-	1+	1+	1+	1+	1+	1+	1+
Recurrent patient response to Gefitinib	-	Y	-	-	-	-	-	-	-	-	-	-	-	-
PDX response to Gefitinib	-	Y	-	-	N	-	-	-	-	N	N	N	N	-

14/21

FIG. 4C



In vivo tumor growth curve




FIG. 4D





FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

Cell Line	Sex/age (yr)	Primary site	Type	Treatment	Outcome
NCC-HN1	F/25	Tongue	Recurrence	Surgery, palliative chemotherapy	Distant metastases, died of disease 5 mo after diagnosis of recurrence
NCC-HN43	M/65	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Distant metastases, died of disease 5 mo after initial diagnosis
NCC-HN19	M/48	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Distant metastases, died of disease 7 mo after initial diagnosis
NCC-HN64	M/76	Tongue	Primary	Surgery	Distant metastases, Lost to Follow-up
NCC-HN26	M/60	Hard palate	Primary	Surgery, adjuvant chemoradiation therapy	Alive 3 yr without disease
NCC-HN73	F/48	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Alive 2 yr without disease

* All cell lines were established from tumours that were histologically proven to be squamous cell carcinoma and obtained from surgical material derived from lymph node metastases; Abbreviations: F, female; M, male

FIG. 13

FIG. 15

Primary cell line	EGFR Copy no.	EGFR mutation (Sanger sequencing)						Other mutations (Lung colon Panel)
		Exon 18	Exon 19		Exon 20		Exon 21	
			G719C G>T G719A G>C G719S G>A	ΔE746-A750	ΔL747-S752	2361 G>A Q787Q		
NCC-HN1	7.5	-	-	-	GG	-	-	ALK, MET, PTEN, TP53
NCC-HN43	6.1	-	-	-	GG	-	-	TP53
NCC-HN19	21.4	-	-	-	AA	-	-	-
NCC-HN64	5.5	-	-	-	AA	-	-	ALK, TP53
NCC-HN26	5.7	-	-	-	AG	-	-	TP53
NCC-HN73	20.9	-	-	-	GG	-	-	PIK3CA, TP53